baricitinib

Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease. Gilead CEO On Remdesivir: Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir received an emergency use authorization designation in...

The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs.  The Analyst Goldman Sachs' Jami Rubin...

Argus analyst Katelyn Bayone believes shares of Eli Lilly and Co (NYSE: LLY) are fairly valued at around $81, which prompted her to downgrade the stock from Buy to Hold. According to Bayone, shares are trading near their 52-week high and also at a superior valuation versus its peers. In fact, the...

Credit Suisse is bullish on Eli Lilly and Co (NYSE: LLY), saying the recent FDA delay on rheumatoid arthritis drug baricitinib is only a short-term setback for the pharma major. But, the brokerage acknowledges the stock could see some modest weakness on the news. Eli Lilly along with its partner...

There has been a three-month delay in the Food and Drug Administration Prescription Drug User Fee Act date for Incyte Corporation (NASDAQ: INCY)'s partnered rheumatoid arthritis drug, baricitinib. The U.S. approval and launch of the drug is now expected in Q2 2017, JMP Securities analysts said in...

Biotech stocks are regaining some lost momentum after Wednesday's Trump-inspired selloff that took a toll on the sentiment on pharma sector. The weakness was so stark that it made CNBC's Brian Sullivan tweet that biotechs/healthcare was the only sector to have been left out of what seemed...

Biopharma companies did not have much to write home about in the year 2016, as negative news flow on price gouging hit many stocks in the space. The SPDR S&P Biotech (ETF) (NYSE: XBI) and the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) are down 13.93 percent and 20.36 percent,...

Marc Goodman of UBS lowered his EPS estimates for Eli Lilly and Co (NYSE: LLY) after the company announced that its Alzheimer's drug solanezumab failed to slow the cognitive decline in patients. Goodman, who previously had modeled about $1.1 billion for 2020 solanezumab sales, has cut 2016 EPS...

Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...